June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
The safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC
Jun 19, 2025, 18:18

The safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC

International Association for the Study of Lung Cancer shared a post on LinkedIn:

“In this study, Zhao et al. evaluated the safety, efficacy, and pharmacokinetics of deulorlatinib in ALK-positive NSCLC. The results demonstrated its potential to become a new treatment option in this patient population.”

Title: Safety, Efficacy, and Biomarker Analysis of Deulorlatinib (TGRX-326) in Anaplastic Lymphoma Kinase-Positive NSCLC: A Multicenter, Open-Label, Phase 1/1b Trial

Authors: Shen Zhao, Huaqiang Zhou, Nong Yang, Zhehai Wang, Wenjian Jin, Yuxiang Ma, Jinhui Xue, Xingya Li, Yunpeng Liu, Rui Meng, Jianying Zhou, Ying Cheng, Yongsheng Wang, Zhuang Yu, Yu Cao, Yuanyuan Zhao, Yan Huang, Wenfeng Fang, Yang Zhang, Shaodong Hong, Bo Wu, Yanxia Shi, Jingrong Cao, Mingyan Xu, Xiaoni Zhang, Longyu Hu, Bo Peng, Yunpeng Yang, Li Zhang, Hongyun Zhao

Read the Full Article.

NSCLC